$Rituximab for refractory granulomatous eye disease$
Código QR

Rituximab for refractory granulomatous eye disease

Elyse E Lower1,2 Robert P Baughman,1 Adam H Kaufman31Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USAObjective: To determine the effectiven...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lower EE, Baughman RP, Kaufman AH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/4403196810ac4e698ac7c5da40ffb2cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4403196810ac4e698ac7c5da40ffb2cf
record_format	dspace
spelling	oai:doaj.org-article:4403196810ac4e698ac7c5da40ffb2cf2021-12-02T09:09:23ZRituximab for refractory granulomatous eye disease1177-54671177-5483https://doaj.org/article/4403196810ac4e698ac7c5da40ffb2cf2012-10-01T00:00:00Zhttp://www.dovepress.com/rituximab-for-refractory-granulomatous-eye-disease-a11184https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Elyse E Lower1,2 Robert P Baughman,1 Adam H Kaufman31Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USAObjective: To determine the effectiveness of rituximab therapy for patients with granulomatous disease of the eye.Methods: Retrospective review was undertaken of cases seen at a single institution for ocular antineutrophil cytoplasmic antibody-associated vasculitis or sarcoidosis with persistent ocular disease despite systemic therapy. All patients were treated with rituximab and followed for at least 6 months.Results: Nine patients were identified (five with antineutrophil cytoplasmic antibody-associated vasculitis, four with sarcoidosis), and all were treated for at least 6 months. Eight experienced improvement of eye disease and were able to reduce prednisone and other drug therapies. One patient remained stable, but still required high dosages of prednisone. All five patients with lung disease improved with rituximab therapy. Rituximab treatment was well tolerated. Two patients discontinued the drug due to leukopenia; however, both patients reinstituted rituximab at modified doses.Conclusion: Rituximab therapy was effective in controlling granulomatous ocular disease in most cases. The drug was corticosteroid-sparing and effective in refractory cases, with no severe adverse events encountered.Keywords: sarcoidosis, wegener&rsquo;s, ANCA, cyclophosphamideLower EEBaughman RPKaufman AHDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1613-1618 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Lower EE Baughman RP Kaufman AH Rituximab for refractory granulomatous eye disease
description	Elyse E Lower1,2 Robert P Baughman,1 Adam H Kaufman31Department of Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA; 2Oncology Hematology Care, Cincinnati, OH, USA; 3Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USAObjective: To determine the effectiveness of rituximab therapy for patients with granulomatous disease of the eye.Methods: Retrospective review was undertaken of cases seen at a single institution for ocular antineutrophil cytoplasmic antibody-associated vasculitis or sarcoidosis with persistent ocular disease despite systemic therapy. All patients were treated with rituximab and followed for at least 6 months.Results: Nine patients were identified (five with antineutrophil cytoplasmic antibody-associated vasculitis, four with sarcoidosis), and all were treated for at least 6 months. Eight experienced improvement of eye disease and were able to reduce prednisone and other drug therapies. One patient remained stable, but still required high dosages of prednisone. All five patients with lung disease improved with rituximab therapy. Rituximab treatment was well tolerated. Two patients discontinued the drug due to leukopenia; however, both patients reinstituted rituximab at modified doses.Conclusion: Rituximab therapy was effective in controlling granulomatous ocular disease in most cases. The drug was corticosteroid-sparing and effective in refractory cases, with no severe adverse events encountered.Keywords: sarcoidosis, wegener&rsquo;s, ANCA, cyclophosphamide
format	article
author	Lower EE Baughman RP Kaufman AH
author_facet	Lower EE Baughman RP Kaufman AH
author_sort	Lower EE
title	Rituximab for refractory granulomatous eye disease
title_short	Rituximab for refractory granulomatous eye disease
title_full	Rituximab for refractory granulomatous eye disease
title_fullStr	Rituximab for refractory granulomatous eye disease
title_full_unstemmed	Rituximab for refractory granulomatous eye disease
title_sort	rituximab for refractory granulomatous eye disease
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/4403196810ac4e698ac7c5da40ffb2cf
work_keys_str_mv	AT loweree rituximabforrefractorygranulomatouseyedisease AT baughmanrp rituximabforrefractorygranulomatouseyedisease AT kaufmanah rituximabforrefractorygranulomatouseyedisease
_version_	1718398240422887424

Rituximab for refractory granulomatous eye disease

Ejemplares similares